Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.

SG&A Expenses: Vertex vs. Zoetis - A Decade of Growth

__timestampVertex Pharmaceuticals IncorporatedZoetis Inc.
Wednesday, January 1, 20143054090001643000000
Thursday, January 1, 20153770800001532000000
Friday, January 1, 20164328290001364000000
Sunday, January 1, 20174960790001334000000
Monday, January 1, 20185576160001484000000
Tuesday, January 1, 20196584980001638000000
Wednesday, January 1, 20207704560001726000000
Friday, January 1, 20218401000002001000000
Saturday, January 1, 20229447000002009000000
Sunday, January 1, 202311366000002151000000
Monday, January 1, 202414643000002318000000
Loading chart...

Unlocking the unknown

SG&A Expenses: A Tale of Two Giants

In the competitive landscape of pharmaceuticals, understanding the financial dynamics of industry leaders is crucial. Over the past decade, Vertex Pharmaceuticals Incorporated and Zoetis Inc. have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses.

Vertex Pharmaceuticals: A Steady Climb

From 2014 to 2023, Vertex Pharmaceuticals saw a consistent rise in SG&A expenses, growing by approximately 272%. This upward trend reflects the company's strategic investments in marketing and administrative capabilities, crucial for maintaining its competitive edge in the biotech sector.

Zoetis Inc.: Leading the Pack

Zoetis Inc., a leader in animal health, maintained a robust SG&A expenditure, with a 31% increase over the same period. By 2023, Zoetis's expenses were nearly double those of Vertex, underscoring its expansive market reach and operational scale.

These insights highlight the strategic financial maneuvers of these pharmaceutical giants, offering a glimpse into their operational priorities and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025